Amarin reported $18.97M in Selling and Administration Expenses for its fiscal quarter ending in December of 2025.





Selling And Administration Expenses Change Date
AbbVie USD 3.63B 54M Jun/2026
Alnylam Pharmaceuticals USD 347.92M 65.41M Jun/2026
Amarin USD 18.97M 1.03M Dec/2025
AstraZeneca USD 5.8B 735M Jun/2026
BioCryst Pharmaceuticals USD 63.98M 31.8M Jun/2026
DBV Technologies USD 13.4M 8.14M Mar/2026
GlaxoSmithKline GBP 2.19B 75M Jun/2026
Halozyme Therapeutics USD 57M 10.71M Jun/2026
Heron Therapeutics USD 23.74M 605K Dec/2025
Ionis Pharmaceuticals USD 130.07M 20.92M Jun/2026
Nektar Therapeutics USD 11.87M 1.7M Mar/2026
Neurocrine Biosciences USD 383.1M 64.6M Jun/2026
Novartis USD 3.24B 101M Jun/2026